Skip to main content

Table 1 Demographic characteristics of all subjects combined and stratified by macular neovascularization (MNV) type

From: The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration

  Total (43 eyes) Type 1 (26 eyes) Type 2 (12 eyes) Type 3 (5 eyes) p
Mean age (95% CI), years 78 (76.14–80.46) 77.44 (74.38–80.5) 80 (76.25–83.75) 78.2 (73.59–82.81) 0.529
Sex, male/female 14/28 9/16 4/9 1/4 0.774
Mean follow-up (95% CI), years 2.09 (1.8–2.38) 2.01 (1.67–2.35) 2.49 (1.79–3.19) 1.55 (1.04–2.06) 0.276
Mean anti-VEGF injections (95% CI), n 10.58 (8.07–13.09) 10.31 (7.4–13.22) 10.93 (6.14–18.52) 8 (3.12–12.88) 0.754
Anti-VEGF agent, n
 Aflibercept 18 12 5 1  
 Bevacizumab 7 5 1 1  
 Ranibizumab 5 1 2 2  
 Combination 14 7 6 1  
Mean visual acuity, logMAR
 Baseline 0.691 0.549 1.110 0.426 0.012*
 Endpoint 0.733 0.620 1.147 0.329 0.006**
  1. CI confidence interval
  2. *p ≤ 0.05, **p ≤ 0.01